Susquehanna Fundamental Investments LLC Sells 91,637 Shares of Caribou Biosciences, Inc. (NASDAQ:CRBU)

Susquehanna Fundamental Investments LLC decreased its stake in shares of Caribou Biosciences, Inc. (NASDAQ:CRBU) by 84.4% during the second quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 16,967 shares of the company’s stock after selling 91,637 shares during the period. Susquehanna Fundamental Investments LLC’s holdings in Caribou Biosciences were worth $28,000 at the end of the most recent reporting period.

Other institutional investors and hedge funds also recently added to or reduced their stakes in the company. AQR Capital Management LLC bought a new position in shares of Caribou Biosciences during the 2nd quarter valued at $30,000. Point72 DIFC Ltd lifted its holdings in Caribou Biosciences by 389.4% in the second quarter. Point72 DIFC Ltd now owns 30,157 shares of the company’s stock valued at $49,000 after acquiring an additional 23,995 shares during the period. Point72 Asia Singapore Pte. Ltd. bought a new stake in shares of Caribou Biosciences during the 2nd quarter valued at about $52,000. The Manufacturers Life Insurance Company increased its position in shares of Caribou Biosciences by 16.8% during the 2nd quarter. The Manufacturers Life Insurance Company now owns 36,489 shares of the company’s stock valued at $60,000 after purchasing an additional 5,244 shares during the last quarter. Finally, China Universal Asset Management Co. Ltd. increased its position in shares of Caribou Biosciences by 66.5% during the 1st quarter. China Universal Asset Management Co. Ltd. now owns 17,024 shares of the company’s stock valued at $88,000 after purchasing an additional 6,798 shares during the last quarter. Hedge funds and other institutional investors own 77.51% of the company’s stock.

Caribou Biosciences Price Performance

CRBU opened at $1.87 on Friday. The company has a 50 day simple moving average of $2.02 and a two-hundred day simple moving average of $2.74. The firm has a market cap of $168.89 million, a P/E ratio of -1.29 and a beta of 2.27. Caribou Biosciences, Inc. has a 1-year low of $1.50 and a 1-year high of $8.33.

Caribou Biosciences (NASDAQ:CRBU) last posted its quarterly earnings results on Tuesday, August 6th. The company reported ($0.42) EPS for the quarter, beating analysts’ consensus estimates of ($0.46) by $0.04. The business had revenue of $3.46 million for the quarter, compared to analysts’ expectations of $3.31 million. Caribou Biosciences had a negative return on equity of 34.76% and a negative net margin of 372.78%. Equities analysts anticipate that Caribou Biosciences, Inc. will post -1.76 earnings per share for the current year.

Wall Street Analyst Weigh In

Several analysts recently issued reports on the stock. Royal Bank of Canada restated an “outperform” rating and set a $14.00 target price on shares of Caribou Biosciences in a research report on Wednesday, August 7th. HC Wainwright reissued a “buy” rating and set a $9.00 price objective on shares of Caribou Biosciences in a research report on Tuesday, September 3rd. One investment analyst has rated the stock with a hold rating and three have assigned a buy rating to the stock. Based on data from MarketBeat, Caribou Biosciences currently has a consensus rating of “Moderate Buy” and a consensus target price of $11.25.

Caribou Biosciences Company Profile

Caribou Biosciences, Inc, a clinical-stage biopharmaceutical company, engages in the development of genome-edited allogeneic cell therapies for the treatment of hematologic malignancies in the United States and internationally. Its lead product candidate is CB-010, an allogeneic anti-CD19 CAR-T cell therapy that is in phase 1 clinical trial to treat relapsed or refractory B cell non-Hodgkin lymphoma.